drugset / Trial / NCT04524455
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined with continuous intravenous infusion (cIV) blinatumomab.
Timeline
- Start
- 2020-10-02
- Primary completion
- 2023-01-24
- Completion
- 2023-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMG 404 | Monoclonal antibody | — | Intravenous |
| Subject | Blinatumomab | Monoclonal antibody | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |